Total Payments
$2,253
2024 Payments
$195.29
Companies
25
Transactions
131
Medicare Patients
1,953
Medicare Billing
$255,776
Payment Breakdown by Category
Food & Beverage$1,784 (79.2%)
Education$468.57 (20.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,784 | 120 | 79.2% |
| Education | $468.57 | 11 | 20.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Theravance Biopharma, Inc. | $520.77 | 32 | $0 (2018) |
| Merck Sharp & Dohme LLC | $314.15 | 26 | $0 (2024) |
| Astellas Pharma US Inc | $251.36 | 8 | $0 (2020) |
| Janssen Products, LP | $158.95 | 2 | $0 (2019) |
| Gilead Sciences, Inc. | $136.13 | 9 | $0 (2024) |
| Janssen Biotech, Inc. | $135.08 | 11 | $0 (2021) |
| Insmed, Inc. | $124.28 | 5 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $104.90 | 7 | $0 (2023) |
| Shionogi Inc | $83.12 | 5 | $0 (2024) |
| ViiV Healthcare Company | $81.65 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $195.29 | 11 | Amgen Inc. ($43.59) |
| 2023 | $116.74 | 7 | Paratek Pharmaceuticals, Inc. ($41.98) |
| 2022 | $155.30 | 9 | Paratek Pharmaceuticals, Inc. ($33.24) |
| 2021 | $87.82 | 7 | Gilead Sciences, Inc. ($26.35) |
| 2020 | $95.57 | 5 | Astellas Pharma US Inc ($39.99) |
| 2019 | $534.17 | 31 | Merck Sharp & Dohme Corporation ($138.27) |
| 2018 | $509.66 | 32 | Theravance Biopharma, Inc. ($230.32) |
| 2017 | $558.42 | 29 | Theravance Biopharma Inc. ($290.45) |
All Payment Transactions
131 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/04/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: HIV | ||||||
| 09/09/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.06 | General |
| 07/01/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: Infections and Infectious Diseases | ||||||
| 05/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.22 | General |
| 04/29/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Infections and Infectious Diseases | ||||||
| 04/22/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $13.64 | General |
| Category: Respiratory | ||||||
| 03/04/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: Bone Health | ||||||
| 02/06/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: HIV | ||||||
| 02/05/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: Bone Health | ||||||
| 10/26/2023 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: Hepatitis B Vaccine | ||||||
| 08/21/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: ANTIBIOTIC | ||||||
| 07/24/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: ANTIBIOTIC | ||||||
| 05/15/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: Infections and Infectious Diseases | ||||||
| 03/06/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: Infections and Infectious Diseases | ||||||
| 02/27/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: ANTIBIOTIC | ||||||
| 02/07/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.20 | General |
| 12/12/2022 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $26.46 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 10/24/2022 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $11.96 | General |
| Category: HIV | ||||||
| 10/10/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: ANTIBIOTIC | ||||||
| 09/26/2022 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: Infections and Infectious Diseases | ||||||
| 08/15/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: ANTIBIOTIC | ||||||
| 05/16/2022 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), ISENTRESS, DIFICID | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/09/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.02 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 465 | 816 | $130,703 | $59,651 |
| 2022 | 4 | 421 | 837 | $123,538 | $53,370 |
| 2021 | 7 | 496 | 1,132 | $158,878 | $69,332 |
| 2020 | 9 | 571 | 1,212 | $164,979 | $73,423 |
Total Patients
1,953
Total Services
3,997
Medicare Billing
$255,776
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 163 | 456 | $59,280 | $27,568 | 46.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 177 | 181 | $39,820 | $17,805 | 44.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 79 | 112 | $22,848 | $10,177 | 44.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 46 | 67 | $8,755 | $4,100 | 46.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 180 | 545 | $70,850 | $29,745 | 42.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 123 | 125 | $27,500 | $12,883 | 46.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 62 | 92 | $11,960 | $5,687 | 47.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 43 | 47 | $9,588 | $3,676 | 38.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 13 | 28 | $3,640 | $1,379 | 37.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 218 | 813 | $105,665 | $45,269 | 42.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 104 | 104 | $22,880 | $10,957 | 47.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 80 | 113 | $14,735 | $6,906 | 46.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 58 | 64 | $13,056 | $5,030 | 38.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 12 | 12 | $2,100 | $1,031 | 49.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 12 | 13 | $338.00 | $101.01 | 29.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 12 | 13 | $104.00 | $39.00 | 37.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 225 | 784 | $101,920 | $45,856 | 45.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 125 | 125 | $27,500 | $13,932 | 50.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 81 | 134 | $17,420 | $6,592 | 37.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 47 | 54 | $11,016 | $4,443 | 40.3% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 15 | 15 | $2,625 | $1,151 | 43.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 19 | 25 | $3,250 | $954.80 | 29.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 16 | 20 | $390.00 | $154.44 | 39.6% |
| 80048 | Blood test, basic group of blood chemicals | Office | 2020 | 14 | 18 | $390.00 | $151.26 | 38.8% |
| 80076 | Liver function blood test panel | Office | 2020 | 12 | 15 | $360.00 | $122.23 | 34.0% |
About Dr. David Cox, MD
Dr. David Cox, MD is a Infectious Disease healthcare provider based in Greenwood, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1861474231.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Cox, MD has received a total of $2,253 in payments from pharmaceutical and medical device companies, with $195.29 received in 2024. These payments were reported across 131 transactions from 25 companies. The most common payment nature is "Food and Beverage" ($1,784).
As a Medicare-enrolled provider, Cox has provided services to 1,953 Medicare beneficiaries, totaling 3,997 services with total Medicare billing of $255,776. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Greenwood, IN
- Active Since 11/18/2005
- Last Updated 01/13/2022
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1861474231
Products in Payments
- VIBATIV (Drug) $520.77
- PREZCOBIX (Drug) $171.62
- ZERBAXA (Drug) $148.46
- Arikayce (Drug) $124.28
- NUZYRA (Drug) $104.90
- Symtuza (Drug) $96.15
- ISENTRESS (Drug) $88.44
- Fetroja (Drug) $83.12
- DIFICID (Drug) $48.86
- Mytesi (Drug) $46.78
- EVENITY (Biological) $43.59
- AVYCAZ (Drug) $40.75
- DOVATO (Drug) $39.91
- PIFELTRO (Drug) $28.39
- CRESEMBA (Drug) $27.66
- HETLIOZ (Drug) $26.46
- SYMTUZA (Drug) $26.26
- XYWAV (Drug) $25.69
- Cresemba (Drug) $18.74
- Vabomere (Drug) $17.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.